Content Conference Coverage Conferences EASL 2016
EASL 2016: Hepatitis B Treatment Linked to Colorectal and Cervical Cancer
- Details
- Category: HBV Treatment
- Created on Friday, 03 June 2016 00:00
People with hepatitis B who were treated with nucleoside/nucleotide antivirals did not have an overall higher rate of malignancies, but did show an increased incidence of colorectal and cervical cancer, underlining the need for regular screening, according to a study presented at the recent EASL International Liver Congress in Barcelona.
EASL 2016: Antiviral Therapy Linked to Less Liver Cancer and Death in People with Mild Hepatitis B
- Details
- Category: HBV Treatment
- Created on Tuesday, 10 May 2016 00:00
Treatment with nucleoside/nucleotide antiviral therapy was associated with longer overall survival and reduced risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for hepatitis B patients with high viral load but minimal liver inflammation -- a group generally not prioritized for treatment --according to a report presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona.
EASL 2016: Tenofovir Alafenamide Works Well Against Hepatitis B with Less Effect on Bones and Kidneys
- Details
- Category: Experimental HBV Drugs
- Created on Sunday, 17 April 2016 00:00
The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with less detrimental effects on bone and kidney biomarkers, according to a pair of studies presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity
- Details
- Category: Experimental HBV Drugs
- Created on Tuesday, 26 April 2016 00:00
NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA, and hepatitis B "e" antigen (HBeAg), showing greater activity when combined with pegylated interferon, researchers reported at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona.
EASL 2016: Portugal's Roll-Out of Hepatitis C DAA Therapy Achieves Impressive Outcomes
- Details
- Category: HCV Treatment
- Created on Wednesday, 27 April 2016 00:00
Roll-out of hepatitis C therapy using direct-acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows. Overall, 96% of treated patients had a sustained virological response (SVR) to therapy, with a 100% response rate seen in some sub-groups. Treatment also worked well for people with liver cirrhosis and treatment response was unaffected by HIV coinfection, previous hepatitis C therapy, or older age.
More Articles...
- Coverage of the 2016 EASL International Liver Congress
- EASL 2016: Shifting Hepatitis C Treatment to Primary Care Providers Could Expand Availability
- EASL 2016: International Liver Congress Underway this Week in Barcelona
- EASL 2016: DAAs for Hepatitis C Achieve Excellent Outcomes in Real-World Settings
- EASL 2016: ABT-493 + ABT-530 Works Well for Patients Who Did Not Respond to Prior DAAs
- EASL 2016: AbbVie Pangenotypic Combination Achieves High Cure Rate for Genotype 3 Hepatitis C
- EASL 2016: Vaccines for HIV and Hepatitis C Could Potentially Be Administered Together
- EASL 2016: Adolescents with Hepatitis C Achieve High Cure Rates with Sofosbuvir/Ledipasvir
- EASL 2016: Novel Therapy RG-101 Plus Antivirals Could Cure Hepatitis C in 4 Weeks
- EASL 2016: $300 Hepatitis C Combination with Ravidasvir to Enter Clinical Trials
- EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients
- EASL 2016: WHO Issues New Hepatitis C Guidelines, EASL Guidelines Update Coming
- EASL 2016: High Incidence of HCV Reinfection Among HIV+ Gay Men in Western Europe
- EASL 2016: Sofosbuvir/ Ledipasvir for 6 Weeks Cures Acute Hepatitis C in HIV-Negative People
- EASL 2016: People Treated for Hepatitis C Have Unexpectedly High Rate of Liver Cancer Recurrence
- EASL 2016: Hepatitis C Treatment May Not Stop Progression to Advanced Liver Disease
- EASL 2016: HCV Therapy Improves Quality of Life for People Who Inject Drugs, Reinfection Risk Remains
- EASL 2016: Cost of Eliminating Viral Hepatitis Must Consider Social as Well as Medical Factors
- EASL 2016: How Generic Direct-Acting Antivirals Are Changing the Hepatitis C Treatment Landscape
- EASL 2016: Low-Cost Generic Hepatitis C Drugs Match Branded Products in Viral Response
- EASL 2016: Liver Associations Worldwide Call for Elimination of Viral Hepatitis
- EASL 2016: Does Having HIV Affect Response to Hepatitis C Treatment?
- EASL 2016: Sofosbuvir/ Velpatasvir Cures 95% of HIV/HCV Coinfected People
- EASL 2016: Emricasan May Improve Inflammation and Liver Function in People with Cirrhosis
- EASL 2016: NorUrsodeoxycholic Acid Help Rare Bile Duct Disease with No Current Treatment
Web Design and Development by